Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00754767 · ClinicalTrials.gov registry record · Phase 4
L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
A Phase 4 study, sponsored by HealthPartners Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00754767 is a Phase 4 study that was terminated before completion, run by HealthPartners Institute. The registered enrollment target is 2 participants.
The verdict
NCT00754767, a Phase 4 study, was terminated before completion, sponsored by HealthPartners Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: L-carnitine L-tartrate may prevent peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well L-carnitine L-tartrate works in preventing peripheral neuropathy caused by chemotherapy in women with metastatic breast cancer.
Interventions
- OTHER placebo
- DRUG L-carnitine L-tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-01-02 |
| Est. Completion | 2008-05-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00754767
The ClinicalTrials.gov registry entry for NCT00754767 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00754767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00754767 about?
NCT00754767 is a clinical study titled "L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer". RATIONALE: L-carnitine L-tartrate may prevent peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well L-carnitine L-tartrate works in preventing peripheral neuropathy caused by chemotherapy in women with metastatic breast cancer.
What is the current status of trial NCT00754767?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2007-01-02. Estimated completion is 2008-05-02.
What interventions are being tested in trial NCT00754767?
The interventions under investigation include: placebo (OTHER), L-carnitine L-tartrate (DRUG).
Who is sponsoring clinical trial NCT00754767?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.